Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Ulcerative colitis (UC) is a chronic immune-mediated inflammatory disorder of the colon
(IBD) that is hypothesized to be related to exposure to environmental risk factors leading to …

Background The global prevalence of ulcerative colitis is increasing, and induction and
maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety …

Background Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have
potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further …

Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

Objective Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being
investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and …

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with an
unknown etiology. IBD is composed of two different disease entities: Crohn's disease (CD) …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with
increasing incidence worldwide. Crohn's disease might result from a complex interplay …

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis
(UC), is characterized by chronic inflammation, a relapsing and remitting clinical course …

A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was
recently implicated in various autoimmune disorders. Tregs are responsible for the …